1. Scrip

Akeega Approval Means Three-Way PARP/Anti-Androgen Race In Prostate Cancer Is On

 
• By Alaric DeArment

Despite the advantage of a single pill, the J&J drug could have the potential disadvantage of a narrower label in both the US and EU and Lynparza/Zytiga’s potentially higher efficacy.

J&J's Akeega won FDA approval on 11 August • Source: Shutterstock

The anticipated three-way competition between PARP inhibitor and anti-androgen drug combinations in adults with deleterious or suspected deleterious BRCA-positive metastatic castration-resistant prostate cancer (mCRPC) is now official with the US Food and Drug Administration approval of Akeega (niraparib and abiraterone acetate), from Johnson & Johnson’s Janssen Pharmaceutical Cos.

Still, while the single pill could make for a convenience advantage, Akeega has two potential disadvantages in the form of...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from New Products

More from Scrip

BerGenBio Plumps For Oncoinvent From Long List Of 50 Suitors

 
• By Kevin Grogan

The merger with a fellow Norwegian biotech comes a few months after its lead asset, bemcentinib, bit the dust.

In Brief: Opus Gears Up For FDA Filing In Presbyopia

 
• By Sushmita Panda

Data from a second pivotal trial support a filing in the US for Opus Genetics’ phentolamine ophthalmic solution, to treat presbyopia.

BlissBio Goes Solo On HER2-Targeting ADC After Eisai Exit

 
• By Dexter Jie Yan

BlissBio is to single-handedly move BB-1701, its eribulin-containing, HER2-targeting antibody-drug conjugate, into a global pivotal Phase II/III program for HER2-expressing, Enhertu-resistant breast cancer.